Metsera, Inc. is a clinical-stage biotechnology company developing injectable and oral nutrient stimulated hormone (NuSH) analog peptides to treat obesity, overweight and related conditions. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization, or HALO, half-life extending platform and its MOMENTUM oral NuSH analog peptide delivery platform to deliver highly differentiated product candidates. Its product pipeline includes MET-097i, MET-233i / MET-233i + MET-097i and MET-224o. MET-097i, its advanced product candidate, is a fully biased, monthly, subcutaneously injectable ultra-long acting GLP-1 RA. MET-233i is a subcutaneously injectable ultra-long-acting amylin analog, with enhanced solubility and miscibility with its other NuSH analog peptides. MET-224o is an oral, fully biased ultra-long acting GLP-1 RA. The Company's pipeline also includes MET-002o, MET-AMYo, MET-034i, MET-067i and MET-PYYi.
